---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021648"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:15:17.665994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth

## Summary
- Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
- Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.
- Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.
- Full-year 2024 outlook reiterated: net sales growth of at least 16%.
- Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations.

## SEC filing metadata
- accession: 0001628280-24-021648
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/cdxc-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021648
- JSON: https://secwatch.observer/filing/0001628280-24-021648.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021648.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported first quarter of 2024 results: revenue $22.2 million, net income $0.5 million, EPS $(0.01) per share. Guidance reaffirmed.
  - Period: first quarter of 2024
  - Revenue: $22.2 million
  - Net income: $0.5 million
  - EPS: $(0.01) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.